Inventor · disambiguated record
Steven Dworetzky
Also filed as: DWORETZKY STEVEN · DWORETZKY STEVEN I
20 granted patents·7 pending applications·110 citations·filing 1995–2025
94Inventor score
Files withKNOPP BIOSCIENCES LLC11BRISTOL MYERS SQUIBB CO6ARETEIA THERAPEUTICS INC3BIOHAVEN THERAPEUTICS LTD2BRISTOL MYERS SQUIBB1
Top patents by PatentIndex Score
27 records- 0194US9642840B2Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disordersKNOPP BIOSCIENCES LLC·Filed 2014·Granted May 9, 2017·10 cites·16 claims
- 0294US9468630B2Compositions and methods for treating conditions related to increased eosinophilsKNOPP BIOSCIENCES LLC·Filed 2013·Granted Oct 18, 2016·14 cites·25 claims
- 0392US6469042B1Fluoro oxindole derivatives as modulators if KCNQ potassium channelsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Oct 22, 2002·32 cites·12 claims
- 0489US11026928B2Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophilsKNOPP BIOSCIENCES LLC·Filed 2018·Granted Jun 8, 2021·3 cites·40 claims
- 0588US10980783B2Compositions and methods for treating conditions related to increased eosinophilsKNOPP BIOSCIENCES LLC·Filed 2019·Granted Apr 20, 2021·2 cites·26 claims
- 0688US9763918B2Compositions and methods for treating chronic urticariaKNOPP BIOSCIENCES LLC·Filed 2014·Granted Sep 19, 2017·4 cites·64 claims
- 0786US10383856B2Compositions and methods for treating conditions related to increased eosinophilsKNOPP BIOSCIENCES LLC·Filed 2016·Granted Aug 20, 2019·2 cites·24 claims
- 0885US2025099437A1Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophilsARETEIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0984US10028940B2Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disordersKNOPP BIOSCIENCES LLC·Filed 2017·Granted Jul 24, 2018·3 cites·28 claims
- 1083US10383857B2Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophilsKNOPP BIOSCIENCES LLC·Filed 2018·Granted Aug 20, 2019·2 cites·55 claims
- 1183US10195183B2Compositions and methods for treating chronic urticariaKNOPP BIOSCIENCES LLC·Filed 2017·Granted Feb 5, 2019·3 cites·22 claims
- 1282US11612589B2Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophilsARETEIA THERAPEUTICS INC·Filed 2020·Granted Mar 28, 2023·1 cites·128 claims
- 1379US12138249B2Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophilsARETEIA THERAPEUTICS INC·Filed 2023·Granted Nov 12, 2024·0 cites·14 claims
- 1476US10828284B2Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophilsKNOPP BIOSCIENCES LLC·Filed 2014·Granted Nov 10, 2020·1 cites·34 claims
- 1576US6831080B2Cinnamide derivatives as KCNQ potassium channel modulatorsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Dec 14, 2004·11 cites·27 claims
- 1674US7041496B2DNA encoding rodent KCNQ2 potassium channelBRISTOL MYERS SQUIBB·Filed 2002·Granted May 9, 2006·2 cites·5 claims
- 1770US10456381B2Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disordersKNOPP BIOSCIENCES LLC·Filed 2018·Granted Oct 29, 2019·0 cites·36 claims
- 1869US6893858B2Human kcnq5 potassium channel, methods and compositions thereofBRISTOL MYERS SQUIBB CO·Filed 2001·Granted May 17, 2005·4 cites·4 claims
- 1964US2025312316A1Methods of use for kv7 channel activatorsBIOHAVEN THERAPEUTICS LTD·Filed 2025·Application pending·0 cites
- 2057US12370176B2Methods of use for KV7 channel activatorsBIOHAVEN THERAPEUTICS LTD·Filed 2020·Granted Jul 29, 2025·0 cites·11 claims
- 2155US5621007AMethod for regulation of transmembrane chloride conductanceBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Apr 15, 1997·16 cites·4 claims
- 2254US2009005304A1Human KCNQ5 potassium channel, methods and compositions thereofBRISTOL MYERS SQUIBB CO·Filed 2007·Application pending·0 cites
- 2350US2005064491A1Human KCNQ5 potassium channel, methods and compositions thereofFiled 2004·Application pending·0 cites
- 2445US2013273557A1Compounds and methods of modulating mitochondrial bioenergetic efficiency through an interaction with atp synthase (complex v) and its subunitsGRIBKOFF VALENTIN·Filed 2011·Application pending·0 cites
- 2542US6855829B23-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related diseaseBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Feb 15, 2005·0 cites·8 claims
- 2640US2006257934A1Cell-based assay for the quantitative high throughput screening of gamma-aminobutyric acid-induced halide transportTERTYSHNIKOVA SVETLANA·Filed 2006·Application pending·0 cites
- 2740US2002183335A12, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulatorsFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Steven Dworetzky files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →